REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
Trial details
- Registry ID
- NCT03721978
- Drugs studied
- CELLECTRA™-5PSP, VGX-3100
TrialRedline tracks 6 clinical trials sponsored by Inovio Pharmaceuticals: 2 Phase 3, 1 Phase 2 / 3, 3 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03721978 | CELLECTRA™-5PSP, VGX-3100 | Completed | 2022-08-23Actual |
| REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)NCT03185013 | Electroporation (EP), VGX-3100 | Completed | 2020-07-08Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureNCT04642638 | CELLECTRA® 2000, INO-4800 | Terminated | 2022-09-13Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersNCT04588428 | CELLECTRA™ 2000, INO-4700 | Completed | 2023-01-19Actual |
| Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)NCT03180684 | CELLECTRA™ 2000, Imiquimod 5% Cream, VGX-3100 | Completed | 2020-07-23Actual |
| VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2NCT03499795 | CELLECTRA™ 5PSP, VGX-3100 | Completed | 2020-06-16Actual |
Names as written in the registry records.
NCT04588428 · Inovio Pharmaceuticals
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Frequency of Adverse Events in Part 1 Measure: Percentage of Participants with Adverse Events in Part 1 Measure: Frequency of Injection Site Reactions in Part 1 Measure: Percentage of Participants with Injection Site Reactions in Part 1 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 1 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 1 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 1 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 1 Measure: Percentage Antigen Specific Cellular Immune Response in Part 1 Measure: Percentage of Seroconverted Participants in Part 1 Measure: Percentage of Participants with Overall Immune Response in Part 1 Measure: Frequency of Adverse Events in Part 2 Measure: Percentage of Participants with Adverse Events in Part 2 Measure: Frequency of Injection Site Reactions in Part 2 Measure: Percentage of Participants with Injection Site Reactions in Part 2 Measure: Frequency of Adverse Events of Special Interest (AESIs) in Part 2 Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs) in Part 2 Measure: Geometric Mean Titers (GMTs) of MERS-CoV Antigen Specific Binding Antibodies in Part 2 Measure: Percentage MERS-CoV Antigen Specific Neutralizing Antibodies in Part 2 Measure: Percentage Antigen Specific Cellular Immune Response in Part 2 Measure: Percentage of Seroconverted Participants in Part 2 Measure: Percentage of Participants with Overall Immune Response in Part 2. After: Measure: Part 1: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs), Graded by Severity, and Treatment-related AEs Measure: Part 1: Percentage of Participants With Injection Site Reactions Measure: Part 1: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 6 Measure: Part 1: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Geometric Mean Fold Rise (GMFR) of INO-4700 Antigen Specific Binding Antibody at Week 10 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 6 Measure: Part 1: Percentage Neutralizing Antibody Responders at Week 10 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 6 Measure: Part 1: Percentage of Antigen Specific Cellular Immune Responders at Week 10 Measure: Part 2: Percentage of Participants With Adverse Events Measure: Part 2: Percentage of Participants With Injection Site Reactions Measure: Part 2: Percentage of Participants With Adverse Events of Special Interest (AESIs) Measure: Part 2: Geometric Mean Concentration (GMC) of INO-4700 Antigen Specific Binding Antibody Measure: Part 2: Percentage Neutralizing Antibody Responders Measure: Part 2: Percentage of Antigen Specific Cellular Immune Responders.